New antiviral treatment for COVID-19 will be mostly set aside for use in older unvaccinated individuals and immunocompromised Ontarians
A new antiviral drug that can be used to treat COVID-19 will be primarily set aside for use in older unvaccinated individuals and immunocompromised Ontarians.
The Ford government has released new eligibility guidelines that provide the first look at how it will distribute its limited supply of Pfizer’s Paxlovid pill, the first shipment of which arrived in the province last week.
The government says that it is prioritizing individuals at “the highest risk of severe outcomes,” including unvaccinated Ontarians age 60 and up and unvaccinated Ontarians aged 50 and up who also have one or more specific risk factors.
The government will also make all immunocompromised individuals aged 18 and up eligible, regardless of their vaccination status, as well as all unvaccinated First Nation, Inuit and Métis individuals aged 50 and up.
In order to access the drug those eligible will have to first test positive for COVID-19 and the Ford government says that it is now introducing “expanded COVID-19 assessment centres” where Ontarians will be able to access both testing and “outpatient therapeutics,” such as Paxlovid.
It says that the testing centres will have access to multiple testing options, including rapid tests, to asses those who may be eligible for treatment.
However, not all assessment centres will have the drug on hand.
According to data from the clinical trials, the Paxlovid pill was found to be 89 per cent effective at reducing the risk of hospitalization and death after a full course of treatment (three pills twice daily for five days in a row).
The Ontario government has said that it expects to receive approximately 10,000 courses of treatment in January.
“Given the very limited supply of antivirals, not all patients who meet the clinical eligibility criteria will be guaranteed access to treatment,” the government warns on a new website set up to provide information about antiviral treatments.
Paxlovid was approved by Health Canada on Jan. 17.
CTVNews.ca Top Stories
Doctors ask Liberal government to reconsider capital gains tax change
The Canadian Medical Association is asking the federal government to reconsider its proposed changes to capital gains taxation, arguing it will affect doctors' retirement savings.
Keeping these exotic pets is 'cruel' and 'dangerous,' Canadian animal advocates say
Canadian pet owners are finding companionship beyond dogs and cats. Tigers, alligators, scorpions and tarantulas are among some of the exotic pets they are keeping in private homes, which pose risks to public safety and animal welfare, advocates say.
Prince William and wife Kate thank public for birthday messages for son Louis
Prince William and his wife Kate thanked the public for their messages which had been sent to mark the sixth birthday of their youngest son Louis on Tuesday.
She was the closest she'd ever been to meeting her biological father. Then life dealt her a blow
Anne Marie Cavner was the closest she'd ever been to meeting her biological father, but then life dealt her a blow. From an unexpected loss to a host of new relationships, a DNA test changed her life, and she doesn't regret a thing.
How quietly promised law changes in the 2024 federal budget could impact your day-to-day life
The 2024 federal budget released last week includes numerous big spending promises that have garnered headlines. But, tucked into the 416-page document are also series of smaller items, such as promising to amend the law regarding infant formula and to force banks to label government rebates, that you may have missed.
Fire engulfs old Edmonton municipal airport hangar
A historical hangar at the former Edmonton municipal airport beside the NAIT main campus was on fire Monday night.
RCMP uncovers plot to sell drones and equipment to Libya
The RCMP says it has uncovered a ploy to sell Chinese drones and military equipment to Libya illegally.
Which foods have the most plastics? You may be surprised
'How much plastic will you have for dinner, sir? And you, ma'am?' While that may seem like a line from a satirical skit on Saturday Night Live, research is showing it's much too close to reality.
'Catch-and-kill' strategy to be a focus as testimony resumes in Trump hush money case
A veteran tabloid publisher was expected to return to the witness stand Tuesday in Donald Trump's historic hush money trial.